With all three of Pfizer's drugs the main effect is to reduce liver fat. All of those types of drugs have failed in NASH. If I had to hazard a guess, I think once liver scarring starts occurring an inflammatory state is induced that is not completely reversible by fat reduction alone. Which would explain why fat reduction drugs aren't working. Leronlimab on the other hand is anti-inflammatory, can reduce white fat and stop loss of metabolic action.